Introducing The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency »
Breakthrough Solutions at the Speed of Science
Committed to restoring health and hope to patients with rare diseases driven by pathologic mineralization and intimal proliferation.Our Focus
Collaboration is the core of what we do. Driven by empathy, compassion and tireless innovation, we bring together leading talent to create life-saving therapies for patients and their families.Help us deliver hope
Patients & Families
People with rare diseases need effective therapies. We’re partnering with patients, their families, and their healthcare providers to advance life-changing therapeutic solutions and save lives.Access More
We are developing a potential first-in-class enzyme therapy to address pathologic mineralization and intimal proliferation.
INZ-701 increases inorganic pyrophosphate (PPi) and adenosine levels by cleaving extracellular ATP throughout the body – mimicking the function of the membrane-bound ENPP1 protein.
INZ-701 is formulated for subcutaneous delivery and designed to have prolonged exposure and elimination phases, making dosing possible at infrequent intervals.
INZ-701 is a novel enzyme therapy that can target genetic and non-genetic diseases which involve low levels of PPi and adenosine – including ENPP1 Deficiency, ABCC6 Deficiency and Calciphylaxis.
Join a Clinical Trial
You are part of the solution.
We are enrolling patients with ENPP1 Deficiency or ABCC6 Deficiency (PXE) in the first clinical trials for a potential new treatment. With your participation, we can better understand this disease and help inform possible future treatment options.Join a clinical Trial